Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00129753 |
Recruitment Status :
Withdrawn
(Terminated due to slow accrual.)
First Posted : August 12, 2005
Last Update Posted : November 8, 2018
|
Sponsor:
M.D. Anderson Cancer Center
Information provided by:
M.D. Anderson Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : | Withdrawn |
---|---|
Actual Primary Completion Date : | September 5, 2006 |
Actual Study Completion Date : | September 5, 2006 |